Dashboard
Manage Tickers

ABCL AbCellera Biologics Inc.

Nasdaq abcellera.com


$ 5.65 $ -0.25 (-4.28 %)    

Friday, 17-Oct-2025 19:51:28 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 5.59
$ 5.70
$ 5.39 x 20
$ 5.75 x 43
$ 5.41 - $ 5.79
$ 1.89 - $ 6.52
4,584,979
na
1.67B
$ 1.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-20-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-21-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

stock-market-today-dow-futures-slip-sp-500-rises-amid-mixed-tradeberkshire-occidental-fermi-in-focus
Stock Market Today: Dow Futures Slip, S&P ...
10/02/2025 09:50:44

U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices w...

why-did-abcelleras-stock-jump-over-7-after-hours
Why Did AbCellera's Stock Jump Over 7% Aft...
10/02/2025 06:15:08

AbCellera's stock rose 7.72% in after-hours trading following an 18.49% gain during regular trading, with a strong performa...

abcellera-doses-first-participants-in-phase-1-clinical-trial-of-abcl575-for-treatment-of-moderate-to-severe-atopic-dermatitis
AbCellera Doses First Participants In Phas...
08/27/2025 13:11:05

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
08/18/2025 17:35:28

expert-outlook-abcellera-biologics-through-the-eyes-of-4-analysts
Expert Outlook: AbCellera Biologics Throug...
08/08/2025 18:02:05

stifel-maintains-buy-on-abcellera-biologics-lowers-price-target-to-7
Stifel Maintains Buy on AbCellera Biologic...
08/08/2025 13:41:00

Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and lowers the price target from $8 to $7.

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
08/08/2025 12:08:44

abcellera-initiates-dosing-of-participants-in-a-phase-1-clinical-trial-of-abcl635-co-initiated-a-phase-1-clinical-trial-of-abcl575-which-is-being-developed-for-the-treatment-of-moderate-to-severe-atopic-dermatitis
AbCellera Initiates Dosing Of Participants...
08/07/2025 21:11:57

abcellera-biologics-q2-eps-012-beats-015-estimate-sales-17084m-beat-5824m-estimate
AbCellera Biologics Q2 EPS $(0.12) Beats $...
08/07/2025 20:33:07

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

galaxy-digital-blaize-holdings-verizon-and-other-big-stocks-moving-higher-on-monday
Galaxy Digital, Blaize Holdings, Verizon A...
07/21/2025 14:16:31

keybanc-maintains-overweight-on-abcellera-biologics-raises-price-target-to-10
Keybanc Maintains Overweight on AbCellera ...
07/14/2025 12:06:40

Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target f...

leerink-partners-assumes-abcellera-biologics-at-outperform-announces-price-target-of-5
Leerink Partners Assumes AbCellera Biologi...
07/07/2025 12:39:13

Leerink Partners analyst Faisal Khurshid assumes AbCellera Biologics (NASDAQ:ABCL) with a Outperform rating and announces Pr...

health-canada-grants-no-objection-letter-for-abcelleras-abcl575-advancing-investigational-ox40l-antibody-for-ad-treatment
Health Canada Grants No Objection Letter f...
05/30/2025 17:02:48

ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of at...

truist-securities-maintains-buy-on-abcellera-biologics-lowers-price-target-to-10
Truist Securities Maintains Buy on AbCelle...
05/16/2025 17:40:41

Truist Securities analyst Robyn Karnauskas maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and lowers the price targe...

abcellera-receives-health-canada-authorization-to-initiate-phase-1-clinical-trial-of-abcl635-for-vasomotor-symptoms-due-to-menopause
AbCellera Receives Health Canada Authoriza...
05/14/2025 21:01:14

Core News & Articles
AbCellera Announces The Federal Circuit Up...
05/12/2025 19:33:55

The Federal Circuit rejects Bruker Cellular's invalidity challenge to AbCellera's patent for microfluidic devices and t...

reported-friday-abcelleras-abcl575-matches-clinical-benchmark-and-demonstrates-extended-half-life-in-preclinical-ad-studies
Reported Friday, AbCellera's ABCL575 Match...
05/12/2025 07:40:17

ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-...

abcellera-biologics-q1-eps-014-inline-sales-424m-miss-753m-estimate
AbCellera Biologics Q1 EPS $(0.14), Inline...
05/08/2025 20:42:55

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This...

Core News & Articles
Earnings Scheduled For May 8, 2025
05/08/2025 08:33:13

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION